Cytori Therapeutics, a developer of cell therapies based on autologous adipose-derived regenerative cells (ADRCs), has obtained Russian approval for its Celution 800 system.
The Celution system and its related products including ADRCs will be sold into Russia for plastic surgery and select soft tissue therapies, through the company's distribution partner Human Stem Cells Institute of Moscow (HSCI).
HSCI will sell Celution system and related products initially to physicians and clinics who are seeking to perform soft tissue procedures such as injections, autologous fat grafting and tissue repair procedures.
Cytori Therapeutics marketing & sales executive vice-president Clyde Shores said the regulatory achievement and the distribution partnership with HSCI gives the company immediate access to the Russian market through an established and scientifically driven organization with a sales and marketing team already trained and knowledgeable in cell therapy.
"We anticipate beginning to see the incremental impact from Russian sales starting in the second half of 2012," Shores added.
"This approval is an important achievement and helps fulfill our stated 2012 goal to obtain additional market approvals for our technology."
